<DOC>
	<DOCNO>NCT00568984</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate efficacy blood glucose control combination therapy repaglinide metformin compare conventional treatment sulphonylurea metformin monotherapy type 2 diabetes</brief_summary>
	<brief_title>Efficacy Safety Repaglinide Metformin Combined Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes least 3 month No previous treatment diabetes HbA1c 7.012.0 % Body Mass Index ( BMI ) 19.040.0 kg/m2 Type 1 diabetes Known unstable/untreated proliferative retinopathy Uncontrolled treated/untreated hypertension Pregnancy , breastfeeding , intention become pregnant judge use inadequate contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>